Court finds headgear used on Simplus and Eson 2 CPAP masks infringes
ResMed patent
MUNICH--(BUSINESS WIRE)--
ResMed (NYSE: RMD) (ASX: RMD), the world’s leading tech-driven medical
company and innovator in sleep apnea and respiratory care, today
announced the results of a court and patent office ruling in Germany in
ResMed’s favor.
A trial court ruling from the Munich District Court states that the
headgear used on two Fisher & Paykel CPAP masks – the Simplus full face
and Eson 2 nasal mask – infringes ResMed patent EP 2 373 368 B1 in
Germany. In a separate decision, the Opposition Division of the European
Patent Office had already decided that the patent asserted against
Fisher & Paykel is valid. Each decision may be appealed by Fisher &
Paykel.
“We applaud the Munich District Court for reaching this just finding,
and are exploring all options in light of the fact that Fisher & Paykel
is selling CPAP masks with headgear that infringes a valid ResMed patent
in Germany,” said ResMed Chief Administrative Officer and Global General
Counsel David Pendarvis.
“We will continue to defend our intellectual property here and wherever
necessary to ensure that patients worldwide continue to receive the
high-quality care they deserve,” Pendarvis said.
About ResMed
ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company
with more than 6 million cloud-connected devices for daily remote
patient monitoring, changes lives with every breath. Its award-winning
devices and software solutions help treat and manage sleep apnea,
chronic obstructive pulmonary disease and other respiratory conditions.
Its 6,000-member team strives to improve patients’ quality of life,
reduce the impact of chronic disease and save healthcare costs in more
than 120 countries. ResMed.com
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181022005912/en/
ResMed
For media:
Jayme Rubenstein
+1 858.836.6798
[email protected]
or
For
investors:
Amy Wakeham
+1 858.836.5000
[email protected]
Source: ResMed